Evaxion picks gonorrhea as second target for vaccine candidate
Encouraging pre-clinical results for Evaxion’s EVX-BV2 candidate have led the firm to add a second target indication, gonorrhea.
by andreas lønstrup, translated by catherine brett
Evaxion Biotech has announced that the firm has chosen sexually transmitted disease gonorrhea as the second target of its EVX-B2 vaccine candidate.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Evaxion Biotech's lung cancer candidate ready for clinic
For subscribers
GSK to invest USD 1.2bn in infectious disease battle
For subscribers
.jpg&w=384&q=75)
